We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Penumbra's Q2 2026 revenues rose 14.9%, led by thrombectomy and Embolization and Access growth.
PEN's international revenues grew 7.6% in Q2, with sales spanning more than 100 countries.
Penumbra's Q2 operating margin fell to 10.5% as SG&A growth outpaced revenue growth.
Penumbra, Inc.’s (PEN - Free Report) robust product portfolio expansion is poised to drive growth in the upcoming quarters. The company’s international expansion efforts are thriving. Unfavorable foreign exchange and a dull macroeconomic scenario may pose operational risks for PEN.
In the past year, shares of this Zacks Rank #3 (Buy) company have risen 21.1% against the industry’s 3% decline. The S&P 500 composite has risen 16.4%.
The global healthcare provider company has a market capitalization of $13.18 billion. PEN has an earnings yield of 1.6% against the industry’s negative 1.7% yield.
Tailwinds for Penumbra
Portfolio Expansion: Penumbra is extending thrombectomy technology across peripheral and neurovascular use cases through Lightning, Flash, Bolt and THUNDERBOLT, alongside complementary embolization and access products. In the second quarter of 2026, revenues increased 14.9% year over year, with thrombectomy up 12.5% and Embolization and Access up 20.0%.
For the first half of 2026, those categories grew 12.3% and 21.8%, respectively. THUNDERBOLT received U.S. FDA clearance and a CE Mark in June 2026, extending CAVT into acute ischemic stroke in both markets. The April 2026 STORM-PE readout remains supportive of CAVT adoption in pulmonary embolism. The Zacks Consensus Estimate for revenues is pinned at $1.60 billion for 2026 and at $1.81 billion for 2027.
International Growth: Penumbra continues to build its presence outside the United States through direct sales teams and distributors, while supporting providers in more than 100 countries. International revenues rose 7.6% year over year in the second quarter of 2026 and 11.7% in the first half of 2026. International sales represented 21.7% of second-quarter 2026 revenues. THUNDERBOLT’s June 2026 CE Mark adds a new neurovascular CAVT product for Europe, providing another route to expand utilization as regulatory clearances and commercial resources scale.
What Ails PEN?
Foreign Exchange Exposure: International revenues represented 21.7% of total sales in the second quarter of 2026, and most sales outside the United States are billed in local currencies, primarily euros. Penumbra does not currently hedge foreign exchange exposure, so currency movements can affect reported revenues and net income.
Foreign currency translation adjustments were a $0.5 million loss in the second quarter and a $1.7 million loss in the first half of 2026. Management stated that an immediate 10% adverse currency move would not materially affect net income, but exchange-rate changes can still add variability to reported growth and profitability.
Image Source: Zacks Investment Research
Cost And Macro Sensitivity: Penumbra’s expense base continues to grow faster than revenues. In the second quarter of 2026, SG&A increased 24.1% year over year versus 14.9% revenue growth, reflecting higher personnel, acquisition-related services, marketing events and travel.
Operating income totaled $41.0 million versus $40.8 million a year earlier, while operating margin fell to 10.5% from 12.0%. For the first half of 2026, SG&A rose 24.8% and operating income declined to $79.3 million from $81.2 million. Second-quarter 2026 EPS also missed the Zacks Consensus by 23.5%. Procedure timing and reimbursement variability can further affect results.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2026 earnings has remained unchanged at $4.96 per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.60 billion, indicating a 14% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, sporting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Key Takeaways
Penumbra, Inc.’s (PEN - Free Report) robust product portfolio expansion is poised to drive growth in the upcoming quarters. The company’s international expansion efforts are thriving. Unfavorable foreign exchange and a dull macroeconomic scenario may pose operational risks for PEN.
In the past year, shares of this Zacks Rank #3 (Buy) company have risen 21.1% against the industry’s 3% decline. The S&P 500 composite has risen 16.4%.
The global healthcare provider company has a market capitalization of $13.18 billion. PEN has an earnings yield of 1.6% against the industry’s negative 1.7% yield.
Tailwinds for Penumbra
Portfolio Expansion: Penumbra is extending thrombectomy technology across peripheral and neurovascular use cases through Lightning, Flash, Bolt and THUNDERBOLT, alongside complementary embolization and access products. In the second quarter of 2026, revenues increased 14.9% year over year, with thrombectomy up 12.5% and Embolization and Access up 20.0%.
For the first half of 2026, those categories grew 12.3% and 21.8%, respectively. THUNDERBOLT received U.S. FDA clearance and a CE Mark in June 2026, extending CAVT into acute ischemic stroke in both markets. The April 2026 STORM-PE readout remains supportive of CAVT adoption in pulmonary embolism. The Zacks Consensus Estimate for revenues is pinned at $1.60 billion for 2026 and at $1.81 billion for 2027.
International Growth: Penumbra continues to build its presence outside the United States through direct sales teams and distributors, while supporting providers in more than 100 countries. International revenues rose 7.6% year over year in the second quarter of 2026 and 11.7% in the first half of 2026. International sales represented 21.7% of second-quarter 2026 revenues. THUNDERBOLT’s June 2026 CE Mark adds a new neurovascular CAVT product for Europe, providing another route to expand utilization as regulatory clearances and commercial resources scale.
What Ails PEN?
Foreign Exchange Exposure: International revenues represented 21.7% of total sales in the second quarter of 2026, and most sales outside the United States are billed in local currencies, primarily euros. Penumbra does not currently hedge foreign exchange exposure, so currency movements can affect reported revenues and net income.
Foreign currency translation adjustments were a $0.5 million loss in the second quarter and a $1.7 million loss in the first half of 2026. Management stated that an immediate 10% adverse currency move would not materially affect net income, but exchange-rate changes can still add variability to reported growth and profitability.
Image Source: Zacks Investment Research
Cost And Macro Sensitivity: Penumbra’s expense base continues to grow faster than revenues. In the second quarter of 2026, SG&A increased 24.1% year over year versus 14.9% revenue growth, reflecting higher personnel, acquisition-related services, marketing events and travel.
Operating income totaled $41.0 million versus $40.8 million a year earlier, while operating margin fell to 10.5% from 12.0%. For the first half of 2026, SG&A rose 24.8% and operating income declined to $79.3 million from $81.2 million. Second-quarter 2026 EPS also missed the Zacks Consensus by 23.5%. Procedure timing and reimbursement variability can further affect results.
PEN Stock Estimate Trends
In the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2026 earnings has remained unchanged at $4.96 per share.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.60 billion, indicating a 14% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, sporting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.